

Clinical Practice

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they exist. The article ends with the authors' clinical recommendations.

MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA

ETHAN A. HALM, M.D., M.P.H.,
AND ALVIN S. TEIRSTEIN, M.D.

A 65-year-old man with hypertension and degenerative joint disease presents to the emergency department with a three-day history of a productive cough and fever. He has a temperature of 38.3°C (101°F), a blood pressure of 144/92 mm Hg, a respiratory rate of 22 breaths per minute, a heart rate of 90 beats per minute, and oxygen saturation of 92 percent while breathing room air. Physical examination reveals only crackles and egophony in the right lower lung field. The white-cell count is 14,000 per cubic millimeter, and the results of routine chemical tests are normal. A chest radiograph shows an infiltrate in the right lower lobe. How should this patient be treated?

THE CLINICAL PROBLEM

There are approximately 4 million cases of community-acquired pneumonia in the United States each year, resulting in about 1 million hospitalizations.¹⁻³ Inpatient management of pneumonia is more than 20 times as expensive as outpatient care and costs an estimated \$9 billion a year.^{2,3} The length of hospitalization is the key determinant of inpatient costs.^{2,4} Previous studies have found wide variations in the rates and lengths of hospitalization among patients with pneumonia that are not explained by differences in the characteristics of the patients or the severity of disease.⁵⁻¹⁰ This article focuses on the initial management of community-acquired pneumonia in immunocompetent adults.

From the Department of Health Policy (E.A.H.) and the Divisions of General Internal Medicine (E.A.H.) and Pulmonary and Critical Care Medicine (A.S.T.), Department of Medicine, Mount Sinai School of Medicine, New York. Address reprint requests to Dr. Halm at the Department of Health Policy, Box 1077, Mount Sinai School of Medicine, 1 Gustave L. Levy Pl., New York, NY 10029, or at ethan.halm@mountsinai.org.

STRATEGIES AND EVIDENCE

Diagnosis and Treatment of Pneumonia

Patients with pneumonia usually present with cough (more than 90 percent), dyspnea (66 percent), sputum production (66 percent), and pleuritic chest pain (50 percent), although nonrespiratory symptoms can also predominate.^{11,12} Elderly patients may report fewer symptoms.^{13,14} Unfortunately, information obtained from the history or physical examination cannot rule in or rule out the diagnosis of pneumonia with adequate accuracy.¹⁵ All rigorous definitions of pneumonia require the finding of a pulmonary infiltrate on a chest radiograph.¹⁶

The initial antibiotic regimen should be chosen empirically to cover common typical and atypical pathogens (Table 1). Pneumonia due to atypical organisms (*Mycoplasma pneumoniae*, legionella species, and *Chlamydia pneumoniae*) accounts for 20 to 40 percent of cases and cannot be differentiated from cases due to typical bacteria on the basis of the patient's history, the results of the physical examination, or findings on chest radiographs.^{17,18} Two large observational cohort studies found that antibiotic regimens that cover both typical and atypical organisms are associated with a lower risk of death than regimens that cover just typical bacteria.^{19,20}

Although rigorous data regarding the duration of therapy are limited, most experts recommend a total of 10 to 14 days. Intravenous therapy with antibiotics that have a high level of oral bioavailability (e.g., fluoroquinolones) may be no better than oral therapy with such antibiotics in patients with uncomplicated infections who have a functioning gastrointestinal tract.^{21,22}

Risk Stratification and the Decision to Hospitalize

Between 30 percent and 50 percent of patients who are hospitalized with pneumonia have low-risk cases, many of which could potentially be managed at home.²³⁻²⁵ Indeed, most low-risk patients would prefer to be treated as outpatients.²⁶ Although physicians base the decision about admission on their overall assessment of the severity of illness, they tend to overestimate the risk of death.²⁷ The average 30-day mortality rate among patients with pneumonia is 13.7 percent, but it ranges from 5.1 percent in studies involving ambulatory and hospitalized patients to 36.5 percent in studies involving patients who required intensive care.²⁸

The decision regarding hospitalization should be based on the stability of the patient's clinical condition,

TABLE 1. RECOMMENDATIONS FOR THE INITIAL EMPIRICAL TREATMENT OF PNEUMONIA.

HOSPITAL SETTING	ANTIBIOTIC THERAPY*	COMMON ORGANISMS
General inpatient ward	Third-generation cephalosporin plus a macrolide or doxycycline Antipneumococcal fluoroquinolone β -Lactam- β -lactamase inhibitor plus a macrolide or doxycycline	Typical pathogens: <i>Streptococcus pneumoniae</i> , <i>Haemophilus influenzae</i> Atypical pathogens: <i>Mycoplasma pneumoniae</i> , legionella species, <i>Chlamydia pneumoniae</i>
Intensive care unit No risk of <i>Pseudomonas aeruginosa</i> infection	Third-generation cephalosporin plus an antipneumococcal fluoroquinolone or a macrolide β -Lactam- β -lactamase inhibitor plus antipneumococcal fluoroquinolone or macrolide	Same as above plus <i>Staphylococcus aureus</i> , drug-resistant <i>S. pneumoniae</i> , other gram-negative rods
At risk for <i>P. aeruginosa</i> infection	Antipseudomonal β -lactam plus aminoglycoside plus antipneumococcal fluoroquinolone or macrolide Antipseudomonal β -lactam plus ciprofloxacin	Same as above plus <i>P. aeruginosa</i> , other resistant gram-negative rods

*Third-generation cephalosporins include ceftriaxone (1 to 2 g per day), ceftizoxime (1 to 2 g every 8 to 12 hours), and cefotaxime (1 to 2 g every 6 to 8 hours). Doxycycline is given at a dose of 100 mg every 12 hours. Antipneumococcal fluoroquinolones include levofloxacin (500 mg per day), gatifloxacin (400 mg per day), and moxifloxacin (400 mg per day). Macrolide antibiotics include azithromycin (500 mg per day), erythromycin (500 mg every 6 hours), and clarithromycin (500 mg every 12 hours). A β -lactam- β -lactamase inhibitor is ampicillin-sulbactam (1.5 to 3.0 g every six hours). Antipseudomonal β -lactams include piperacillin-tazobactam (3.375 g every 6 hours) and ceftipime (1 to 2 g every 12 hours).

the risk of death and complications, the presence or absence of other active medical problems, and psychosocial characteristics. Disease-specific prediction rules are available that can be used to assess the initial severity of pneumonia and predict the risk of death. Such instruments can help inform the decision to hospitalize a patient. The most widely used and rigorously studied prediction rule — the Pneumonia Severity Index — has been validated in more than 50,000 patients from a variety of inpatient and outpatient populations (Fig. 1).^{23,29}

The Pneumonia Severity Index is based on data that are commonly available at presentation and stratifies patients into five risk classes in which 30-day mortality rates range from 0.1 percent to 27.0 percent. The higher the score, the higher the risk of death, admission to the intensive care unit, and readmission and the longer the length of stay. Easy-to-use versions of the index are now available on the Internet (<http://ursa.kcom.edu/CAPcalc/default.htm>, <http://ncemi.org>, and <http://www.emedhomom.com/dbase.cfm>)³⁰⁻³² and handheld computers.

An algorithm that uses the Pneumonia Severity Index to judge the appropriateness of admission is shown in Figure 2. Patients in risk classes I, II, and III are at low risk for death, and most can be safely treated as outpatients in the absence of extenuating circumstances.

The availability of oral antibiotics that attain high serum levels has made outpatient treatment even easier to recommend than in the past. An algorithm based on the Pneumonia Severity Index deviates most

from traditional teaching in emphasizing that an age of more than 65 years alone is not an indication for admission.

Some low-risk patients, especially those who are elderly or in class III of the Pneumonia Severity Index, may look sick or be reluctant to be treated at home. Many of these patients may be appropriate candidates for a short stay or 23 hours of inpatient observation. This strategy allows them to receive antibiotic therapy and any needed hydration while their condition is monitored for deterioration. The risk of worsening, although very low, is highest on the day of presentation and decreases considerably thereafter,³³ so patients whose condition is stable throughout the first hospital day should subsequently do well. The few patients who do not have a favorable response to this approach can then be admitted as traditional inpatients.

Patients at moderate risk (class IV of the Pneumonia Severity Index) and high risk (class V) should be hospitalized, given their much higher rates of death and complications. In general, most such patients are elderly and have two or more additional poor prognostic factors, such as serious coexisting conditions, abnormal vital signs, and abnormal laboratory values. All patients with hypoxemia (defined by an oxygen saturation of less than 90 percent or a partial pressure of arterial oxygen of less than 60 mm Hg in a patient who is breathing room air) or serious hemodynamic instability should be hospitalized regardless of their score on the Pneumonia Severity Index. Other indications for admission include suppurative or metastatic disease (empyema, lung abscess, endocarditis, menin-




Figure 1. The Pneumonia Severity Index.

The Pneumonia Severity Index is used to determine a patient's risk of death. The total score is obtained by adding to the patient's age (in years for men or in years - 10 for women) the points assigned for each additional applicable characteristic.

Data have been adapted from Fine et al.²³

gitis, or osteomyelitis) or infection due to high-risk pathogens (e.g., *Staphylococcus aureus*, gram-negative rods, and anaerobes).

Several studies have established the safety and effectiveness of an approach involving an admission-decision algorithm that is based on the Pneumonia Severity Index. The strongest evidence comes from a randomized, controlled trial involving 19 hospitals.²⁵ The hospitals that were randomly assigned to implement the protocol admitted fewer low-risk patients than did the control hospitals (31 percent vs. 49 per-

cent). There were no significant differences between groups in the hospitalization rates among moderate- and high-risk patients for whom the protocol recommended admission. The intervention reduced the overall number of hospital bed-days per patient without any increase in deaths, complications, use of the intensive care unit, or readmissions or any decrement in the health-related quality of life.

This trial confirmed the findings of a study in which a similar triage protocol decreased the initial hospitalization rates among low-risk patients, from 58 per-




Figure 2. Algorithm for Determining Whether a Patient with Community-Acquired Pneumonia Should Be Admitted or Treated as an Outpatient.

cent to 43 percent, without any change in the rates of death, symptom resolution, functional recovery, or patient satisfaction.²⁴ The implementation of a somewhat different (but related) algorithm in urgent care clinics also increased the proportion of low-risk patients who were treated at home without compromising patient outcomes.^{34,35} These studies also confirm that selected low-risk elderly patients with pneumonia can be treated as outpatients with good results. Though this research shows that many low-risk patients who have traditionally been hospitalized can safely be treated at home, many still require or desire

hospitalization. The most common reasons for admitting low-risk patients include the presence of coexisting conditions, patients' preferences, and inadequate home support.³⁶

Criteria for Clinical Stability and Discharge

Once a patient is hospitalized and has received appropriate antibiotic therapy, the most important decision is determining when their condition is clinically stable and they are ready to go home. To be considered ready for discharge, patients should have stable vital signs, have adequate oxygenation while breathing

TABLE 2. CRITERIA FOR DETERMINING THE APPROPRIATENESS OF DISCHARGE.

Patient's vital signs are stable for 24-hour period (i.e., temperature $\leq 37.8^{\circ}\text{C}$ [100°F], respiratory rate ≤ 24 breaths per minute, heart rate ≤ 100 beats per minute, systolic blood pressure ≥ 90 mm Hg, and oxygen saturation $\geq 90\%$ while patient is breathing room air or at base line for patients with chronic obstructive lung disease or those receiving oxygen therapy at home).
Patient is able to take oral antibiotics.
Patient is able to maintain adequate hydration and nutrition.
Patient's mental status is normal (or at his or her base-line level).
Patient has no other active clinical or psychosocial problems requiring hospitalization.

room air, be able to take oral antibiotics and maintain their oral intake, and have returned to their base-line mental status (Table 2). They should also have no other active medical or psychosocial problems that require inpatient management.

Overall, the median time to clinical stability is three days among low-risk patients, four days among moderate-risk patients, and six days among those at high risk.³³ Once a patient's condition becomes stable, the risk of serious clinical deterioration is 1 percent or less, even among the sickest subgroup of patients. Conversely, patients who are discharged before their condition has stabilized have higher risk-adjusted rates of death or readmission and return more slowly to their usual activities.³⁷ Several randomized controlled trials and observational studies corroborate the safety of this type of discharge criteria.^{25,38-43} Although these studies used various designs and ways of defining clinical stability, they all stressed the importance of the resolution of fever, improving respiratory signs or symptoms, the ability to take oral antibiotics, and the absence of other active medical problems.

Similar stability criteria can be used to determine when patients can be switched from parenteral to oral antibiotics. This topic has recently been systematically reviewed.⁴³ In brief, data from randomized controlled trials and prospective studies indicate that early conversion from intravenous to oral therapy does not adversely affect outcomes.^{25,38-41,44-46} In addition, evidence from observational studies suggests that there is no need to observe patients for 24 hours after a switch to oral therapy.^{47,48}

The condition of individual patients will stabilize at different times depending on the initial severity of pneumonia, the presence or absence of coexisting conditions, and the response to therapy. Therefore, practice guidelines, critical pathways, and utilization-management rules should use objective criteria to

determine the appropriateness of discharge rather than rigidly specifying the number of days of hospitalization.

Though the condition of the average patient will become clinically stable on the third or fourth day of hospitalization,³³ patients need to be told that they will probably feel sick for a while. One week after presenting with pneumonia, 80 percent of patients report fatigue and cough and 50 percent report dyspnea and sputum production.¹² It is often a few weeks before all their symptoms resolve and they return to their usual activities.^{11,12,49}

GUIDELINES

Two national subspecialty organizations have published guidelines for the management of community-acquired pneumonia. The guidelines of the Infectious Diseases Society of America (updated in 2000) endorse the use of the Pneumonia Severity Index as providing "a rational foundation for the decision regarding hospitalization."⁵⁰ The recommended admission-decision algorithm is similar to that depicted in Figure 2. The guidelines state that patients in class I or II do not usually require hospitalization, those in class III may require a brief inpatient stay, and those in class IV or V should be hospitalized.

The 2001 guidelines of the American Thoracic Society,⁵¹ although acknowledging the value of prediction rules like the Pneumonia Severity Index, recommend that patients with "multiple risk factors" for a complicated course be admitted. The guidelines list these prognostic factors (many of which are included in the Pneumonia Severity Index), but it does not specify how these data might be used to inform the decision about admission. Both guidelines indicate that old age alone is not a reason for hospitalization.

The American Thoracic Society recommends that patients be switched to oral antibiotics and discharged on the same day that the patient's clinical condition stabilizes, if other medical and social factors permit. The society uses the following criteria for switching therapy to oral antimicrobial agents (which should also apply to the discharge decision): an improvement in cough and dyspnea, a temperature of 37.8°C (100°F) or less on two occasions eight hours apart, a decreasing white-cell count, and a functioning gastrointestinal tract with adequate oral intake. The Infectious Diseases Society of America does not specify discharge criteria but does recommend timely conversion to treatment with highly bioavailable oral agents when the patient's condition becomes stable and he or she can tolerate oral medicines. Both guidelines imply that the average hospital course can probably be shorter than previously thought appropriate, since most patients have an adequate clinical response to therapy within three days.

AREAS OF UNCERTAINTY

The randomized controlled trials supporting our recommendations largely used a new antipneumococcal fluoroquinolone or an advanced macrolide antibiotic (agents that cover both typical and atypical organisms) to treat outpatients. This strategy has been associated with better outcomes than the use of more narrowly focused initial regimens.^{19,20} We are less confident that oral therapy at home with non-first-line regimens, such as treatment with a penicillin or cephalosporin alone, can achieve equally favorable results. Although many experts suggest that a short period of observation in the hospital is appropriate for “sicker-appearing” low-risk patients, there have been no published trials of this approach. There are no definitive data addressing whether the criteria for discharge should vary depending on the pathogen (if known) or the presence or absence of complications. An extended course of intravenous antibiotics is generally recommended for patients with legionella infection, bacteremia due to high-risk organisms (*S. aureus* or gram-negative rods), or suppurative complications (e.g., empyema). Nearly all the studies we reviewed excluded patients with human immunodeficiency virus (HIV) infection. The discharge criteria we highlight are from studies that defined stability as demonstrated by a 24-hour period in which vital signs were normal.^{29,33,37} Other studies have required just an 8-hour or 16-hour period of stable vital signs.^{25,40,41} There are no good data comparing the alternative definitions.

CONCLUSIONS AND RECOMMENDATIONS

We believe that most low-risk patients with pneumonia (those in class I, II, or III of the Pneumonia Severity Index) can be treated at home in the absence of extenuating circumstances. The condition of low-risk patients who are admitted is likely to stabilize very quickly, and these patients may need to spend just a few days in the hospital. Conversely, moderate-risk and high-risk patients (those in class IV and class V, respectively) should be admitted. Once the condition of patients is clinically stable, they should be switched to oral antibiotic therapy and discharged within 24 hours (unless they have other medical or psychosocial problems requiring inpatient management). Before being discharged from the emergency department or the hospital, all patients should be informed about the length of time it will take them to recover and alerted to the signs of clinical worsening that would require urgent medical attention. Although data are lacking, we believe that most patients who have HIV infection and true community-acquired pneumonia can be treated in the same way as any other patients with pneumonia, unless they have advanced HIV disease.

With respect to the case vignette, the patient's Pneumonia Severity Index score is 65 on the basis of his

age. He has no other major risk factors or serious abnormalities in laboratory data or vital signs that increase his risk of a poor outcome. His Pneumonia Severity Index score corresponds to risk class II and a predicted 30-day mortality rate of less than 1 percent. Because his condition is hemodynamically stable, he has adequate oxygenation while breathing room air, and there are no contraindications to outpatient care, we would recommend that he be treated as an outpatient and receive an oral antibiotic that covers both typical and atypical organisms (an advanced macrolide or antipneumococcal fluoroquinolone). Finally, we would recommend that, in the future, the patient receive the pneumococcal vaccine if he has not previously been immunized.

Dr. Halm is supported in part by the Robert Wood Johnson Foundation Generalist Physician Faculty Scholars Program.

REFERENCES

1. Clinical classifications for health policy research: hospital inpatient statistics, 1996. Rockville, Md.: Agency for Health Care Policy and Research, 1999. (AHCPR publication no. 99-0034).
2. Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R. The cost of treating community-acquired pneumonia. *Clin Ther* 1998;20:820-37.
3. Lave JR, Lin CJ, Fine MJ, Hughes-Cromwick P. The cost of treating patients with community-acquired pneumonia. *Semin Respir Crit Care Med* 1999;20:189-97.
4. Fine MJ, Pratt HM, Obrosky DS, et al. Relation between length of hospital stay and costs of care for patients with community-acquired pneumonia. *Am J Med* 2000;109:378-85.
5. Wennberg JE, Freeman JL, Culp WJ. Are hospital services rationed in New Haven or over-utilised in Boston? *Lancet* 1987;1:1185-9.
6. McMahon LF Jr, Wolfe RA, Tedeschi PJ. Variation in hospital admissions among small areas: a comparison of Maine and Michigan. *Med Care* 1989;27:623-31.
7. Burns LR, Wholey DR. The effects of patient, hospital, and physician characteristics on length of stay and mortality. *Med Care* 1991;29:251-71.
8. Cleary PD, Greenfield S, Mulley AG, et al. Variations in length of stay and outcomes for six medical and surgical conditions in Massachusetts and California. *JAMA* 1991;266:73-9.
9. Fine MJ, Singer DE, Phelps AL, Hanusa BH, Kapoor WN. Differences in length of hospital stay in patients with community-acquired pneumonia: a prospective four-hospital study. *Med Care* 1993;31:371-80.
10. McCormick D, Fine MJ, Coley CM, et al. Variation in length of hospital stay in patients with community-acquired pneumonia: are shorter stays associated with worse medical outcomes? *Am J Med* 1999;107:5-12.
11. Fine MJ, Stone RA, Singer DE, et al. Processes and outcomes of care for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team (PORT) cohort study. *Arch Intern Med* 1999;159:970-80.
12. Metlay JP, Fine MJ, Schulz R, et al. Measuring symptomatic and functional recovery in patients with community-acquired pneumonia. *J Gen Intern Med* 1997;12:423-30.
13. Metlay JP, Schulz R, Li YH, et al. Influence of age on symptoms at presentation in patients with community-acquired pneumonia. *Arch Intern Med* 1997;157:1453-9.
14. Mehr DR, Binder EF, Kruse RL, Zweig SC, Madsen RW, D'Agostino RB. Clinical findings associated with radiographic pneumonia in nursing home residents. *J Fam Pract* 2001;50:931-7.
15. Metlay JP, Kapoor WN, Fine MJ. Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination. *JAMA* 1997;278:1440-5.
16. Bartlett JG, Mundy LM. Community-acquired pneumonia. *N Engl J Med* 1995;333:1618-24.
17. Marston BJ, Plouffe JF, File TM Jr, et al. Incidence of community-acquired pneumonia requiring hospitalization: results of a population-based active surveillance study in Ohio. *Arch Intern Med* 1997;157:1709-8.

18. Marrie TJ. Community-acquired pneumonia. *Clin Infect Dis* 1994;18:501-13.
19. Gleason PP, Meehan TP, Fine JM, Galusha DH, Fine MJ. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. *Arch Intern Med* 1999;159:2562-72.
20. Houck PM, MacLehose RF, Niederman MS, Lowery JK. Empiric antibiotic therapy and mortality among Medicare pneumonia inpatients in 10 western states: 1993, 1995, and 1997. *Chest* 2001;119:1420-6.
21. Sanders WE Jr, Morris JF, Alessi P, et al. Oral ofloxacin for the treatment of acute bacterial pneumonia: use of a nontraditional protocol to compare experimental therapy with "usual care" in a multicenter clinical trial. *Am J Med* 1991;91:261-6.
22. Chan R, Hemeryck L, O'Regan M, Clancy L, Feely J. Oral versus intravenous antibiotics for community acquired lower respiratory tract infection in a general hospital: open, randomised controlled trial. *BMJ* 1995;310:1360-2.
23. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. *N Engl J Med* 1997;336:243-50.
24. Atlas SJ, Benzer TI, Borowsky LH, et al. Safely increasing the proportion of patients with community-acquired pneumonia treated as outpatients: an interventional trial. *Arch Intern Med* 1998;158:1350-6.
25. Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK, Feagan BG. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. *JAMA* 2000;283:749-55.
26. Coley CM, Li YH, Medsger AR, et al. Preferences for home vs hospital care among low-risk patients with community-acquired pneumonia. *Arch Intern Med* 1996;156:1565-71.
27. Fine MJ, Hough LJ, Medsger AR, et al. The hospital admission decision for patients with community-acquired pneumonia: results from the pneumonia Patient Outcomes Research Team cohort study. *Arch Intern Med* 1997;157:36-44.
28. Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia: a meta-analysis. *JAMA* 1996;275:134-41.
29. Auble TE, Yealy DM, Fine MJ. Assessing prognosis and selecting an initial site of care for adults with community-acquired pneumonia. *Infect Dis Clin North Am* 1998;12:741-59. [Erratum, *Infect Dis Clin North Am* 2000;14:xi.]
30. Community acquired pneumonia CAP prognostic calculator. (Accessed November 22, 2002, at <http://ursa.kcom.edu/CAPcalc/default.htm>.)
31. Pneumonia Severity Index risk calculator. (Accessed November 22, 2002, at http://www.ncemi.org/cgi-ncemi/edecision.pl?TheCommand=Load&NewFile=community-acquired_pneumonia_mortality_risk&BlankTop=1).
32. Pneumonia Severity Index risk calculator. (Accessed November 22, 2002, at <http://www.emedhome.com/dbase.cfm>.)
33. Halm EA, Fine MJ, Marrie TJ, et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. *JAMA* 1998;279:1452-7.
34. Dean NC, Suchyta MR, Bateman KA, Aronsky D, Hadlock CJ. Implementation of admission decision support for community-acquired pneumonia. *Chest* 2000;117:1368-77.
35. Suchyta MR, Dean NC, Narus S, Hadlock CJ. Effects of a practice guideline for community-acquired pneumonia in an outpatient setting. *Am J Med* 2001;110:306-9.
36. Halm EA, Atlas SJ, Borowsky LH, et al. Understanding physician adherence with a pneumonia practice guideline: effects of patient, system, and physician factors. *Arch Intern Med* 2000;160:98-104.
37. Halm EA, Fine MJ, Kapoor WN, Singer DE, Marrie TJ, Siu AL. Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia. *Arch Intern Med* 2002;162:1278-84.
38. Rhew DC, Riedinger MS, Sandhu M, Bowers C, Greengold N, Weingarten SR. A prospective, multicenter study of a pneumonia practice guideline. *Chest* 1998;114:115-9.
39. Weingarten SR, Riedinger MS, Hobson P, et al. Evaluation of a pneumonia practice guideline in an interventional trial. *Am J Respir Crit Care Med* 1996;153:1110-5.
40. Ramirez JA, Srinath L, Ahkec S, Huang A, Raff MJ. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. *Arch Intern Med* 1995;155:1273-6.
41. Ramirez JA, Vargas S, Ritter GW, et al. Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia. *Arch Intern Med* 1999;159:2449-54.
42. Weingarten SR, Riedinger MS, Varis G, et al. Identification of low-risk hospitalized patients with pneumonia: implications for early conversion to oral antimicrobial therapy. *Chest* 1994;105:1109-15.
43. Rhew DC, Tu GS, Ofman J, Henning JM, Richards MS, Weingarten SR. Early switch and early discharge strategies in patients with community-acquired pneumonia: a meta-analysis. *Arch Intern Med* 2001;161:722-7.
44. Siegel RE, Halpern NA, Almenoff PL, Lee A, Cashin R, Greene JG. A prospective randomized study of inpatient i.v. antibiotics for community-acquired pneumonia: the optimal duration of therapy. *Chest* 1996;110:965-71.
45. Omidvari K, de Boisblanc BP, Karam G, Nelson S, Haponik E, Sumner W. Early transition to oral antibiotic therapy for community-acquired pneumonia: duration of therapy, clinical outcomes, and cost analysis. *Respir Med* 1998;92:1032-9.
46. Hendrickson JR, North DS. Pharmacoeconomic benefit of antibiotic step-down therapy: converting patients from intravenous ceftriaxone to oral cefpodoxime proxetil. *Ann Pharmacother* 1995;29:561-5.
47. Rhew DC, Hackner D, Henderson L, Ellrodt AG, Weingarten SR. The clinical benefit of in-hospital observation in 'low-risk' pneumonia patients after conversion from parenteral to oral antimicrobial therapy. *Chest* 1998;113:142-6.
48. Dunn AS, Peterson KL, Schechter CB, Rabito P, Gotlin AD, Smith LG. The utility of an in-hospital observation period after discontinuing intravenous antibiotics. *Am J Med* 1999;106:6-10.
49. Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Feagan BG. Predictors of symptom resolution in patients with community-acquired pneumonia. *Clin Infect Dis* 2000;31:1362-7.
50. Bartlett JG, Dowell SE, Mandell LA, File TM Jr, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. *Clin Infect Dis* 2000;31:347-82.
51. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. *Am J Respir Crit Care Med* 2001;163:1730-54.